Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY: LLY )

818.93 -10.81 (-1.30%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound
The investment is aimed at ensuring a steady supply of the drugs, which have been grappling with shortages since 2022. 
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market. 
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
An investment in these players today could score a big win down the road. 
Via The Motley Fool
Why Roche Holdings Stock Withered on Wednesday
The company had a dispiriting update to offer about an investigational drug. 
Via The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 20 Years
Via Benzinga
A Glimpse Into The Expert Outlook On Eli Lilly Through 28 Analysts
Via Benzinga
Harvest ETFs (TSX: LLYH, LLYH.U, AMZH, AMZH.U, MSFH, MSFH.U, NVDH, NVDH.U, LLHE, LLHE.U, AMHE, AMHE.U, MSHE, MSHE.U, NVHE, NVHE.U ) Closes the Market
Toronto, Ontario--(Newsfile Corp. - September 11, 2024) - Michael Kovacs, President and CEO, Harvest ETFs, ("Harvest" or the "Company") and... 
Via Newsfile
Topics ETFs
4 No-Brainer Stock Splits to Buy Now
There's a massive reason these stocks should split now. 
Via The Motley Fool
Could Elon Musk Become The World's First Trillionaire? Tesla's Success Could Make It Happen As Early As...
A new study predicts Elon Musk will become the world's first trillionaire if Tesla can regain the $1 trillion market cap level. 
Via Benzinga
Smart Money Is Betting Big In LLY Options
Via Benzinga
Comparative Study: Eli Lilly And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
The company is working on a drug that targets GLP-1 and amylin to improve weight loss. 
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight loss in three months with adult participants. 
Via Benzinga
Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound)
There's a little appreciated reason to own Eli Lilly stock, and it has nothing to do with its medicines. 
Via The Motley Fool
Is Hims & Hers Health the Next Teladoc?
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. 
Via The Motley Fool
Exposures COVID-19
Prediction: These 2 Companies Will Split Their Stocks by 2027
Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes. 
Via The Motley Fool
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children... 
Via Benzinga
Exposures Product Safety
Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
Three stocks stand out for investors to consider as they recently had big selloffs. There are fundamental reasons to believe that these discounts won't last 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately. 
Via Benzinga
This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth.
Eli Lilly has been a big-time winner for investors over the last several decades, and there are many reasons to believe the company is at the forefront of many new growth stories. 
Via The Motley Fool
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
This drugmaker should have a basketful of growth drivers over the next decade. 
Via The Motley Fool
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant? 
Via MarketBeat
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock. 
Via The Motley Fool
AskSlim Market Week - Friday, Sept 6
An analysis and commentary on the financial markets. 
Via Talk Markets
Innovent Bio hopes for plus-sized profits from obesity drug
Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival products to gain a market advantage The executive in charge of... 
Via Benzinga
Topics Retirement
Exposures Pension
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
Exposures Product Safety
Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed
Shares of Eli Lilly hit resistance at the $955 level. Now they are heading lower. These moves are due to investor psychology. 
Via Benzinga
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem
The weight loss drug market may soon be worth $100 billion. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.